| |
This playbook looks at why insolubility is an issue, and the properties that affect solubility, such as the molecule’s structure; its physical attributes (particle size and dissolution rate); its chemical attributes, including compatibility with excipients; and its biological properties. Download now.
|
|
|
Discovering and developing a new drug is a complex and time-consuming endeavor. A carefully devised hit finding strategy is, therefore, essential when looking for validated hit series with a good chance of being developed into drug-like compounds. This ebook considers witch method to use, hit finding trends, and new technologies. Download now.
|
|
| By Nick Paul Taylor Arcutis Biotherapeutics’ topical cream has racked up a second phase 3 win in eczema patients, putting the company on track to file for FDA approval in the indication in the second half of next year. |
|
|
|
By Nick Paul Taylor Eyenovia has its date with the FDA. Fourteen months after being hit with a complete response letter, the eye disease specialist has secured a May 8 date for a decision on its MydCombi ophthalmic spray. |
By Nick Paul Taylor SHL Medical has secured financial support for the next phase of its drug delivery growth plan, bringing on board a consortium of investors that will enable it to add production capacity in the U.S. and Europe. |
By Nick Paul Taylor Allay Therapeutics has added a new name to its star-studded investor syndicate: Evonik. The specialty chemicals company backed the startup after seeing promise in drug delivery technology that is enabled by its biodegradable polymers. |
|
Wednesday, January 25, 2023 | 11am ET / 8am PT This webinar, presented by AmerisourceBergen, will deliver insights to manufacturers and payers covering the need for education and best practices for increasing biosimilar adoption, current product landscape and upcoming product launches, and more. Register now.
|
|
By Fraiser Kansteiner Sanofi may have backed down against Amgen in a recent M&A bidding war, but its initial offer that got the ball rolling on the $28 billion buyout of Horizon Therapeutics suggests the French Pharma has a desire for dealmaking. |
Fierce podcastsDon't miss an episode |
| This week on “The Top Line,” we discuss the latest from the Clinical Trials on Alzheimer’s Disease conference. Plus, we cover the week's news including an investigation into Neuralink, Google’s DeepMind and why things aren't working out for PI3Ks. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
| Multimedia Plan Your ASH’22 Attendance In No Time | Interactive Planner Sponsored by: Ferma.AI, a product of ZoomRx |
| PodcastHow can Medical Affairs divisions bring greater value to their organizations and practitioners every day? Sponsored by: Medscape Medical Affairs |
| eBookSee how digital therapeutics (DTx) combined with patient engagement software offer a new opportunity for life science organizations (LSOs) to better serve and support patients. Download the guide from Health Catalyst to learn more. Sponsored by: Health Catalyst |
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| eBookOrally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
| WhitepaperDid you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
| eBook Download now to learn about the benefits of transitioning from intravenous to subcutaneously administration, the advantages of using prefilled syringes, and explore challenges and solutions for transitioning from vials to prefilled syringes. Sponsored by: Catalent |
| |
|
